Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,139,208
  • Shares Outstanding, K 1,101,090
  • Annual Sales, $ 21,222 M
  • Annual Income, $ 2,738 M
  • 36-Month Beta 0.34
  • Price/Sales 4.33
  • Price/Cash Flow 17.61
  • Price/Book 6.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.42 +3.16%
on 11/15/17
86.37 -2.76%
on 10/25/17
-1.18 (-1.39%)
since 10/24/17
3-Month
78.12 +7.51%
on 08/29/17
89.09 -5.72%
on 10/05/17
+5.13 (+6.51%)
since 08/24/17
52-Week
65.66 +27.92%
on 12/01/16
89.09 -5.72%
on 10/05/17
+15.99 (+23.51%)
since 11/23/16

Most Recent Stories

More News
Psoriatic Arthritis - Pipeline Review, H2 2017 - Research and Markets

The "Psoriatic Arthritis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis...

NVO : 52.22 (+0.73%)
JNJ : 137.57 (+0.20%)
AGN : 174.09 (-0.42%)
ABBV : 94.78 (+0.33%)
AMGN : 170.31 (+0.21%)
PFE : 35.51 (+0.23%)
FSNUF : 78.7560 (-1.37%)
LLY : 83.99 (+0.37%)
RIGL : 4.25 (+0.24%)
NHKFF : 14.4000 (unch)
ACRS : 23.20 (+0.35%)
GLPG : 91.96 (+0.01%)
UCBJF : 72.7800 (+3.25%)
Lilly Inks Deal to Include Dexcom Products in Diabetes System

Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.

LGND : 133.92 (+0.65%)
SCMP : 10.65 (+2.40%)
LLY : 83.99 (+0.37%)
DXCM : 55.61 (+0.47%)
DexCom-Lily Partnership to Boost CGM Platform, Customer Base

DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

PETS : 38.74 (-3.22%)
ABT : 56.07 (+0.48%)
LLY : 83.99 (+0.37%)
DXCM : 55.61 (+0.47%)
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion

Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic...

SCMP : 10.65 (+2.40%)
LLY : 83.99 (+0.37%)
NVS : 85.10 (+0.73%)
GSK : 35.15 (+0.26%)
Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Research Desk Line-up: Abeona Therapeutics Post Earnings Coverage

CLDX : 2.93 (+1.38%)
ABEO : 16.90 (+4.64%)
LLY : 83.99 (+0.37%)
United States $6 Billion Insulin Delivery Devices Market Outlook to 2022 - Major Players are Insulet, Medtronic, Roche, Tandem Diabetes Care, Novo Nordisk, Eli Lilly, Sanofi & Owen Mumford

DUBLIN, November 21, 2017 /PRNewswire/ --

LLY : 83.99 (+0.37%)
MDT : 83.21 (+1.06%)
Dexcom Announces Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem

DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a development agreement with Eli Lilly and Company (NYSE: LLY) to...

LLY : 83.99 (+0.37%)
DXCM : 55.61 (+0.47%)
United Therapeutics PAH Drug's Exclusivity Period Extended

United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

JNJ : 137.57 (+0.20%)
LLY : 83.99 (+0.37%)
GILD : 72.66 (-0.22%)
UTHR : 123.96 (-1.16%)
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance...

LLY : 83.99 (+0.37%)
Health nominee reaped big earnings from drug industry tenure

WASHINGTON (AP) — Newly disclosed financial records show that President Donald Trump's nominee to become Health and Human Services secretary reaped big earnings during his tenure as a top pharmaceutical...

LLY : 83.99 (+0.37%)
HMSY : 16.18 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Key Turning Points

2nd Resistance Point 84.59
1st Resistance Point 84.13
Last Price 84.03
1st Support Level 83.35
2nd Support Level 83.03

See More

52-Week High 89.09
Last Price 84.03
Fibonacci 61.8% 80.14
Fibonacci 50% 77.38
Fibonacci 38.2% 74.61
52-Week Low 65.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart